RATIONALE: Ketamine, a non-competitive NMDA receptor antagonist, induces acute effects resembling the positive, negative and cognitive symptoms of schizophrenia. Chronic use has been suggested to lead to persistent schizophrenia-like neurobiological changes. OBJECTIVES: This study aims to test the hypothesis that chronic ketamine users have changes in brain neurochemistry and increased subthreshold psychotic symptoms compared to matched poly-drug users. METHODS: Fifteen ketamine users and 13 poly-drug users were included in the study. Psychopathology was assessed using the Comprehensive Assessment of At-Risk Mental State. Creatine-scaled glutamate (Glu/Cr), glutamate + glutamine (Glu + Gln/Cr) and N-acetyl aspartate (NAA/Cr) were measured in three brain regions-anterior cingulate, left thalamus and left medial temporal cortex using proton magnetic resonance spectroscopy. RESULTS: Chronic ketamine users had higher levels of subthreshold psychotic symptoms (p < 0.005, Cohen's d = 1.48) and lower thalamic NAA/Cr (p < 0.01, d = 1.17) compared to non-users. There were no differences in medial temporal cortex or anterior cingulate NAA/Cr or in Glu/Cr or Glu + Gln/Cr in any brain region between the two groups. In chronic ketamine users, CAARMS severity of abnormal perceptions was directly correlated with anterior cingulate Glu/Cr (p < 0.05, r = 0.61-uncorrected), but NAA/Cr was not related to any measures of psychopathology. CONCLUSIONS: The finding of lower thalamic NAA/Cr in chronic ketamine users may be secondary to the effects of ketamine use compared to other drugs of abuse and resembles previous reports in individuals at genetic or clinical risk of schizophrenia.
RATIONALE: Ketamine, a non-competitive NMDA receptor antagonist, induces acute effects resembling the positive, negative and cognitive symptoms of schizophrenia. Chronic use has been suggested to lead to persistent schizophrenia-like neurobiological changes. OBJECTIVES: This study aims to test the hypothesis that chronic ketamine users have changes in brain neurochemistry and increased subthreshold psychotic symptoms compared to matched poly-drug users. METHODS: Fifteen ketamine users and 13 poly-drug users were included in the study. Psychopathology was assessed using the Comprehensive Assessment of At-Risk Mental State. Creatine-scaled glutamate (Glu/Cr), glutamate + glutamine (Glu + Gln/Cr) and N-acetyl aspartate (NAA/Cr) were measured in three brain regions-anterior cingulate, left thalamus and left medial temporal cortex using proton magnetic resonance spectroscopy. RESULTS: Chronic ketamine users had higher levels of subthreshold psychotic symptoms (p < 0.005, Cohen's d = 1.48) and lower thalamic NAA/Cr (p < 0.01, d = 1.17) compared to non-users. There were no differences in medial temporal cortex or anterior cingulate NAA/Cr or in Glu/Cr or Glu + Gln/Cr in any brain region between the two groups. In chronic ketamine users, CAARMS severity of abnormal perceptions was directly correlated with anterior cingulate Glu/Cr (p < 0.05, r = 0.61-uncorrected), but NAA/Cr was not related to any measures of psychopathology. CONCLUSIONS: The finding of lower thalamic NAA/Cr in chronic ketamine users may be secondary to the effects of ketamine use compared to other drugs of abuse and resembles previous reports in individuals at genetic or clinical risk of schizophrenia.
Authors: R Bartha; P C Williamson; D J Drost; A Malla; T J Carr; L Cortese; G Canaran; R J Rylett; R W Neufeld Journal: Arch Gen Psychiatry Date: 1997-10
Authors: J M Stone; C Dietrich; R Edden; M A Mehta; S De Simoni; L J Reed; J H Krystal; D Nutt; G J Barker Journal: Mol Psychiatry Date: 2012-01-03 Impact factor: 15.992
Authors: Rajesh Narendran; W Gordon Frankle; Richard Keefe; Roberto Gil; Diana Martinez; Mark Slifstein; Lawrence S Kegeles; Peter S Talbot; Yiyun Huang; Dah-Ren Hwang; Leyla Khenissi; Thomas B Cooper; Marc Laruelle; Anissa Abi-Dargham Journal: Am J Psychiatry Date: 2005-12 Impact factor: 18.112
Authors: Ruth Salo; Thomas E Nordahl; Yutaka Natsuaki; Martin H Leamon; Gantt P Galloway; Christy Waters; Charles D Moore; Michael H Buonocore Journal: Biol Psychiatry Date: 2006-11-09 Impact factor: 13.382
Authors: Stephen J Wood; Murat Yücel; R Mark Wellard; Ben J Harrison; Kerrie Clarke; Alex Fornito; Dennis Velakoulis; Christos Pantelis Journal: Schizophr Res Date: 2007-06-18 Impact factor: 4.939
Authors: Shaolin Yang; Betty Jo Salmeron; Thomas J Ross; Zheng-Xiong Xi; Elliot A Stein; Yihong Yang Journal: Psychiatry Res Date: 2009-11-10 Impact factor: 3.222
Authors: P Danos; B Baumann; H G Bernstein; M Franz; R Stauch; G Northoff; D Krell; P Falkai; B Bogerts Journal: Psychiatry Res Date: 1998-04-10 Impact factor: 3.222
Authors: T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta Journal: Psychopharmacology (Berl) Date: 2015-10-05 Impact factor: 4.530
Authors: Ke Xu; John H Krystal; Yuping Ning; Da Chun Chen; Hongbo He; Daping Wang; Xiaoyin Ke; Xifan Zhang; Yi Ding; Yuping Liu; Ralitza Gueorguieva; Zuoheng Wang; Diana Limoncelli; Robert H Pietrzak; Ismene L Petrakis; Xiangyang Zhang; Ni Fan Journal: J Psychiatr Res Date: 2014-12-24 Impact factor: 4.791
Authors: Ni Fan; Ke Xu; Yuping Ning; Robert Rosenheck; Daping Wang; Xiaoyin Ke; Yi Ding; Bin Sun; Chao Zhou; Xuefeng Deng; Waikwong Tang; Hongbo He Journal: Psychiatry Res Date: 2016-01-14 Impact factor: 3.222
Authors: Elias Mouchlianitis; Michael A P Bloomfield; Vincent Law; Katherine Beck; Sudhakar Selvaraj; Naresh Rasquinha; Adam Waldman; Federico E Turkheimer; Alice Egerton; James Stone; Oliver D Howes Journal: Schizophr Bull Date: 2015-12-17 Impact factor: 9.306
Authors: Celia J A Morgan; Chris M Dodds; Hannah Furby; Fiona Pepper; Johnson Fam; Tom P Freeman; Emer Hughes; Christian Doeller; John King; Oliver Howes; James M Stone Journal: Front Psychiatry Date: 2014-12-04 Impact factor: 4.157
Authors: Robert A Chesters; Fiona Pepper; Celia Morgan; Jonathan D Cooper; Oliver D Howes; Anthony C Vernon; James M Stone Journal: Psychopharmacology (Berl) Date: 2021-07-06 Impact factor: 4.415